AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29368632 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of suPAR and syndecan-4 with Pneumonia Severity Index
Number of subjects: 282
Study 29368632 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR ≥10.22 ng/mL and syndecan-4 ≤6.68 ng/mL
Number of subjects: 282
Study 29368656 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based clinical supervision
Number of subjects: 70
Study 29368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care services costs
Number of subjects: 150
Study 29368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall 6-month cost
Number of subjects: 150
Study 29368673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost productive hours costs
Number of subjects: 150
Study 29369091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2.5 µg·kg
Number of subjects: 280
Study 29369091 — intervention group
Group type: COMPARATOR
Intervention: Oral pentobarbital 5 mg·kg
Number of subjects: 280
Study 29369091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 µg·kg (rescue sedation)
Number of subjects: 280
Study 29369664 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, Duloxetine, or Cognitive Behavior Therapy (CBT)
Number of subjects: 94
Study 29369664 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual depressive symptoms on the Hamilton Depression Rating Scale
Number of subjects: 94
Study 29369664 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having a comorbid anxiety disorder diagnosis at study baseline
Number of subjects: 94
Study 29369665 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Intolerance (DI)
Number of subjects: 256
Study 29369678 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning salience
Number of subjects: 80
Study 29369678 — intervention group
Group type: EXPERIMENTAL
Intervention: Global meaning and purpose
Number of subjects: 80
Study 29370183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) resumption after ICH
Number of subjects: 228
Study 29370183 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of OAC resumption
Number of subjects: 228
Study 29370183 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgery respondents' preference for OAC resumption timing
Number of subjects: 228
Study 29370218 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1689
Study 29370218 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 1689
Study 29370229 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (ACs) with or without antiplatelet (AP) therapy
Number of subjects: 28628
Study 29370229 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 28628
Study 29370428 — intervention group
Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (OL-HDF)
Number of subjects: 33
Study 29370428 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HF-HD)
Number of subjects: 33
Study 29370708 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29370795 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight retention intervention including six weeks of interactive daily health texting, exercise assistance with baby carrier, home exercise program, pedometer provision, two live healthy eating and baby feeding workshops, and two 45-min home visits over one year
Number of subjects: 17
Study 29370795 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight retention intervention
Number of subjects: 17
Study 29370811 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone daily added to standard of care
Number of subjects: 0
Study 29370811 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo added to standard of care
Number of subjects: 0
Study 29370824 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity incentive program (HB-PAI) over 6 months
Number of subjects: 84
Study 29370824 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical care over 12 months (Control Group)
Number of subjects: 84
Study 29371177 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mobile phone-based personalized daily step goals
Number of subjects: 64
Study 29371177 — intervention group
Group type: COMPARATOR
Intervention: Constant step goals of 10,000 steps per day (active control)
Number of subjects: 64
Study 29371177 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intervention and control
Number of subjects: 64
Study 29371241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool
Number of subjects: 31579
Study 29371241 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31579
Study 29371263 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic study with longitudinal follow-up
Number of subjects: 1000
Study 29371263 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational models based on Bayesian statistics
Number of subjects: 1000
Study 29371473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, Docetaxel, and Erlotinib
Number of subjects: 50
Study 29371475 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, 10 mg daily
Number of subjects: 2
Study 29371864 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine tablets
Number of subjects: 70
Study 29371864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29372071 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly generated, customised prompts delivered by Microsoft Outlook
Number of subjects: 0
Study 29372071 — intervention group
Group type: EXPERIMENTAL
Intervention: Education session
Number of subjects: 0
Study 29372071 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompts delivered by Microsoft Outlook
Number of subjects: 0
Study 29372071 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 0
Study 29372135 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level TDR
Number of subjects: 599
Study 29372135 — intervention group
Group type: EXPERIMENTAL
Intervention: One-level TDR
Number of subjects: 599
Study 29372135 — intervention group
Group type: COMPARATOR
Intervention: Two-level ACDF
Number of subjects: 599
Study 29372135 — intervention group
Group type: COMPARATOR
Intervention: One-level ACDF
Number of subjects: 599
Study 29372409 — intervention group
Group type: EXPERIMENTAL
Intervention: Solutions provided group
Number of subjects: 556
Study 29372409 — intervention group
Group type: COMPARATOR
Intervention: Solutions withheld group
Number of subjects: 556
Study 29372409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 556
Study 29372461 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (135 mg/m²), oxaliplatin, and S-1 (OIS) regimen
Number of subjects: 44
Study 29372860 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression with interlaminar stabilization (D+ILS)
Number of subjects: 230
Study 29372860 — intervention group
Group type: COMPARATOR
Intervention: Decompression alone (DA)
Number of subjects: 230
Study 29373071 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg once per day until disease progression
Number of subjects: 118
Study 29373602 — intervention group
Group type: COMPARATOR
Intervention: 5 mg BID apixaban
Number of subjects: 37827
Study 29373602 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg BID apixaban
Number of subjects: 37827
Study 29373701 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 75
Study 29373711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone therapy for 24 weeks
Number of subjects: 1
Study 29373711 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pioglitazone follow-up
Number of subjects: 1
Study 29373756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve patients
Number of subjects: 47
Study 29373977 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytosis (platelet count ≥350 × 10^9/L)
Number of subjects: 4005
Study 29373984 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive, strength and neuromuscular exercise group (SNG) with supervised training twice weekly
Number of subjects: 50
Study 29373984 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (CON) consisting of a home-based, low-intensity exercise program
Number of subjects: 50
Study 29373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Number of subjects: 300
Study 29373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 300
Study 29373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium combined berberine
Number of subjects: 300
Study 29373989 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 300
Study 29373993 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 0
Study 29373993 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 0
Study 29373998 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (laser group)
Number of subjects: 80
Study 29373998 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode (LED) therapy (LED group)
Number of subjects: 80
Study 29374048 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid levels in AAA patients
Number of subjects: 498
Study 29374048 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 index levels in AAA patients
Number of subjects: 498
Study 29374048 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 498
Study 29374101 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH)
Number of subjects: 118
Study 29374934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump application
Number of subjects: 0
Study 29375477 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of r-hFSH/r-hLH (900/450 IU)
Number of subjects: 0
Study 29375477 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried formulation of r-hFSH/r-hLH (900/450 IU)
Number of subjects: 0
Study 29377059 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models applied to regional grey matter
Number of subjects: 216
Study 29377059 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models applied to whole-brain grey matter
Number of subjects: 216
Study 29377059 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based classification
Number of subjects: 216
Study 29377378 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, tailored, direct-to-patient, video intervention
Number of subjects: 2684
Study 29377378 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2684
Study 29377378 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, tailored, direct-to-patient, video intervention (n=257)
Number of subjects: 2684
Study 29377566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin dose adjustments
Number of subjects: 1548
Study 29377566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin dose reductions
Number of subjects: 1548
Study 29377566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline haemoglobin
Number of subjects: 1548
Study 29377748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (650 mg EPA and 350 mg DHA daily)
Number of subjects: 11
Study 29377953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir gel, 0.15% 1cc 5 times a day for 6 weeks
Number of subjects: 29
Study 29378049 — intervention group
Group type: EXPERIMENTAL
Intervention: δ13C biomarker measured using fingerstick blood samples
Number of subjects: 326
Study 29378049 — intervention group
Group type: EXPERIMENTAL
Intervention: δ13C biomarker
Number of subjects: 326
Study 29378056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake of 36.6 mg·kg-1·d-1 during early gestation
Number of subjects: 33
Study 29378056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine intake of 50.3 mg·kg-1·d-1 during late gestation
Number of subjects: 33
Study 29378526 — intervention group
Group type: EXPERIMENTAL
Intervention: Saving Babies' Lives care bundle
Number of subjects: 100000
Study 29378526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of implementing the care bundle
Number of subjects: 100000
Study 29378526 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires with service users and care providers
Number of subjects: 100000
Study 29378547 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectables (RLAIs) or paliperidone palmitate (PP) long-acting injectables (LAIs)
Number of subjects: 1065
Study 29378547 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic treatments (APT)
Number of subjects: 1065
Study 29378547 — intervention group
Group type: COMPARATOR
Intervention: Other injectable antipsychotic treatments (APT)
Number of subjects: 1065
Study 29378547 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectables (LAI) APT
Number of subjects: 1065
Study 29378547 — intervention group
Group type: COMPARATOR
Intervention: Oral APT
Number of subjects: 1065
Study 29378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on the four FitnessGram tests (PACER, curl-up, push-up, trunk lift)
Number of subjects: 265
Study 29378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on the four FitnessGram tests
Number of subjects: 265
Study 29378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically fit boys and girls
Number of subjects: 265
Study 29378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically fit girls
Number of subjects: 265
Study 29378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance on the four physical fitness tests
Number of subjects: 265
Study 29378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on the four physical fitness tests
Number of subjects: 265
Study 29378602 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus pegylated interferon-α and ribavirin (PR)
Number of subjects: 249
Study 29378632 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (60 min, 3 days/week) targeting 10,000 steps per day
Number of subjects: 50
Study 29378632 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants at risk for CVD
Number of subjects: 50
Study 29378647 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-POSSUM
Number of subjects: 2749
Study 29378647 — intervention group
Group type: COMPARATOR
Intervention: POSSUM
Number of subjects: 2749
Study 29378647 — intervention group
Group type: COMPARATOR
Intervention: IRCS
Number of subjects: 2749
Study 29378733 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Carboplatin and Docetaxel
Number of subjects: 0
Study 29378789 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenage exercise
Number of subjects: 0
Study 29378790 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous carriers for Gaucher's disease (GD) causing pathogenic mutations
Number of subjects: 1893
Study 29378790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-synonymous variants previously associated with PD
Number of subjects: 1893
Study 29378790 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of unknown significance
Number of subjects: 1893
Study 29379040 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) of the cervical spinal cord
Number of subjects: 0
Study 29379040 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation
Number of subjects: 0
Study 29379652 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (E-PRP) eye drops, 6 times a day for 6 weeks
Number of subjects: 80
Study 29380080 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum respiratory pressures measured through an intubation catheter
Number of subjects: 90
Study 29380080 — intervention group
Group type: COMPARATOR
Intervention: Maximum respiratory pressures measured through a standard mouthpiece
Number of subjects: 90
Study 29380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatment (including Radiofrequency ablation and combination therapy)
Number of subjects: 4978
Study 29380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 4978
Study 29380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RFA and transarterial chemoembolization
Number of subjects: 4978
Study 29380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported non-adherence to immunosuppressive medication
Number of subjects: 504
Study 29380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare worker (HCW) assessment of adherence
Number of subjects: 504
Study 29380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported non-adherence over time
Number of subjects: 504
Study 29380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Main reason for non-adherence
Number of subjects: 504
Study 29380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanations for non-adherence
Number of subjects: 504
Study 29380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication knowledge and trough levels
Number of subjects: 504
Study 29380903 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 29380903 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 29381090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversense CGM system
Number of subjects: 90
Study 29381435 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly
Number of subjects: 79
Study 29381790 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index for pregnant women in Singapore (HEI-SGP)
Number of subjects: 1051
Study 29381792 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors (CCSs)
Number of subjects: 2365
Study 29381792 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemia survivors
Number of subjects: 2365
Study 29381792 — intervention group
Group type: COMPARATOR
Intervention: Siblings of CCSs
Number of subjects: 2365
Study 29381792 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 2365
Study 29381792 — intervention group
Group type: EXPERIMENTAL
Intervention: CCSs treated with cranial radiotherapy (≥20 Gy)
Number of subjects: 2365
Study 29381795 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated PAr (highest quartile)
Number of subjects: 6891
Study 29381798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan fasting
Number of subjects: 29
Study 29381826 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily) with osimertinib (80 mg on Days 1 and 10)
Number of subjects: 36
Study 29381826 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily) with osimertinib (80 mg once daily on Days 1-77)
Number of subjects: 36
Study 29381834 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy consisting of thermal modalities, tissue mobilization, and upper extremity mobility exercises, with 8 weekly in-person sessions.
Number of subjects: 21
Study 29381843 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Number of subjects: 1584
Study 29381843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study 29382367 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CHESS for 12 months
Number of subjects: 280
Study 29382367 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling (TMC) for 12 months
Number of subjects: 280
Study 29382367 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CHESS + TMC for 12 months
Number of subjects: 280
Study 29382367 — intervention group
Group type: COMPARATOR
Intervention: Standard continuing care
Number of subjects: 280
Study 29382379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ultrasonography (US) of the hands, wrists, and feet
Number of subjects: 194
Study 29382379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DAS28
Number of subjects: 194
Study 29382379 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of rheumatoid factor
Number of subjects: 194
Study 29382379 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of monitoring strategy
Number of subjects: 194
Study 29382394 — intervention group
Group type: EXPERIMENTAL
Intervention: meropenem
Number of subjects: 19
Study 29382391 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lopinavir/ritonavir and recombinant interferon-β1b with standard supportive care
Number of subjects: 13
Study 29382391 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard supportive care
Number of subjects: 13
Study 29382504 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced high fat diet (BHFD) for 16 weeks
Number of subjects: 144
Study 29382510 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Renal Functional Reserve (RFR) measured by high oral protein load test
Number of subjects: 110
Study 29382510 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model including demographic and comorbidity covariates, RFR, and intraoperative variables
Number of subjects: 110
Study 29382510 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cell cycle arrest markers at various times
Number of subjects: 110
Study 29382631 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic stimulation (Vim/DRT)
Number of subjects: 18
Study 29382631 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) stimulation
Number of subjects: 18
Study 29382631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation of Vim/DRT and STN
Number of subjects: 18
Study 29382679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 49
Study 29382747 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK2 inhibition
Number of subjects: 0
Study 29382747 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29382815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained anticipation of electric shock
Number of subjects: 0